Other
Deferred Tax Liabilities, Deferred Tax Expense, Right-of-Use Asset
General Dynamics Deferred Tax Liabilities, Deferred Tax Expense, Right-of-Use Asset decreased by 5.6% to $401M in Q4 2025 compared to the prior quarter. Over 3 years (FY 2022 to FY 2025), Deferred Tax Liabilities, Deferred Tax Expense, Right-of-Use Asset shows an upward trend with a 4.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityStable
First reportedQ4 2022
Last reportedQ4 2025Jan 30, 2026
How to read this metric
Changes reflect shifts in the company's lease portfolio and the resulting impact on tax timing.
Detailed definition
This represents the deferred tax impact associated with the accounting treatment of right-of-use assets under lease acco...
Peer comparison
Comparable across all companies reporting under modern lease accounting standards.
Metric ID:
other_deferred_tax_liabilities_deferred_tax_expense_righ_3e451aHistorical Data
4 periods
| Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|
| Value | $356M | $395M | $425M | $401M |
| QoQ Change | — | +11.0% | +7.6% | -5.6% |
| YoY Change | — | +11.0% | +7.6% | -5.6% |
Range$356M – $425M
Avg YoY Growth+4.3%
Median YoY Growth+7.6%
Deferred Tax Liabilities, Deferred Tax Expense, Right-of-Use Asset at Other Companies
Frequently Asked Questions
- What is General Dynamics's deferred tax liabilities, deferred tax expense, right-of-use asset?
- General Dynamics (GD) reported deferred tax liabilities, deferred tax expense, right-of-use asset of $401M in Q4 2025.
- What is the long-term trend for General Dynamics's deferred tax liabilities, deferred tax expense, right-of-use asset?
- Over 3 years (2022 to 2025), General Dynamics's deferred tax liabilities, deferred tax expense, right-of-use asset has grown at a 4.0% compound annual growth rate (CAGR), from $356M to $401M.
- What does deferred tax liabilities, deferred tax expense, right-of-use asset mean?
- Tax liabilities resulting from the timing differences in lease accounting treatments.